Incyte enters into licensing deal valued at up to $900M

Incyte Corp. obtained worldwide rights to an experimental cancer therapy Wednesday under a collaboration and licensing agreement it signed with a Maryland biotechnology company. Under the terms of the deal, Incyte of Wilmington, Del., will make an upfront payment of $150 million to MacroGenics. MacroGenics of Rockville, Md., could receive up to $420 million in potential development and regulatory milestones, and up to $330 million in potential commercial milestones. If t he new drug candidate licensed…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news